Lou Ru, Shao Huawei, Wu Pengcheng
Department of Pathology, The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou 310000, Zhejiang, China.
Department of Burns and Wound Care Centre, The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou 310000, Zhejiang, China.
Am J Transl Res. 2024 Jul 15;16(7):3273-3279. doi: 10.62347/ZLEQ9498. eCollection 2024.
To evaluate the expression of Ribosomal S6 kinase 4 (RSK4) protein in non-small cell lung cancer (NSCLC) tissues and adjacent non-tumor tissues, and to elucidate its correlation with clinicopathological features of NSCLC.
We analyzed 100 NSCLC patients treated at the Second Affiliated Hospital of Zhejiang University School of Medicine from June 2020 to June 2022. Patient demographics and clinical data, including gender, age, history of diabetes, tumor location, degree of tumor differentiation, lymph node metastasis, and clinical stage, were collected. RSK4 protein expression was assessed in tissue samples via immunohistochemical staining.
RSK4 protein was positively expressed in 35.00% of cancerous tissues, significantly lower than the 69.00% observed in adjacent non-tumor tissues (P < 0.05). Patients with lower tumor differentiation, advanced Tumor Node Metastasis (TNM) stages, and lymph node metastases showed significantly reduced RSK4 expression compared to those with higher differentiation, earlier TNM stages, and no lymph node metastases (all P < 0.05). Cox regression analysis indicated that TNM stage, low differentiation, and lymph node metastases significantly influenced RSK4 expression (all P < 0.05). Survival analysis revealed a higher positive prognosis survival rate of 74.29% (26/35) among patients with positive RSK4 expression, versus 53.85% (35/65) in those with negative expression (P < 0.05). Spearman correlation analysis demonstrated a significant positive correlation of RSK4 expression with TNM stage, lymph node metastasis, and patient prognosis (all P < 0.05).
Positive RSK4 expression in NSCLC tissues is significantly correlated with advanced cancer stage, poor differentiation, and presence of lymph node metastasis, suggesting a potential tumor suppressor role for RSK4 in NSCLC. This association underscores its prognostic relevance in NSCLC patients.
评估核糖体S6激酶4（RSK4）蛋白在非小细胞肺癌（NSCLC）组织及癌旁非肿瘤组织中的表达情况，并阐明其与NSCLC临床病理特征的相关性。
我们分析了2020年6月至2022年6月在浙江大学医学院附属第二医院接受治疗的100例NSCLC患者。收集了患者的人口统计学和临床数据，包括性别、年龄、糖尿病史、肿瘤位置、肿瘤分化程度、淋巴结转移情况及临床分期。通过免疫组织化学染色评估组织样本中RSK4蛋白的表达。
RSK4蛋白在35.00%的癌组织中呈阳性表达，显著低于癌旁非肿瘤组织中的69.00%（P<0.05）。与高分化、TNM分期较早且无淋巴结转移的患者相比，肿瘤分化程度较低、肿瘤淋巴结转移（TNM）分期较晚且有淋巴结转移的患者RSK4表达明显降低（均P<0.05）。Cox回归分析表明，TNM分期、低分化及淋巴结转移显著影响RSK4表达（均P<0.05）。生存分析显示，RSK4表达阳性的患者阳性预后生存率为74.29%（26/35），而表达阴性的患者为53.85%（35/65）（P<0.05）。Spearman相关性分析表明，RSK4表达与TNM分期、淋巴结转移及患者预后呈显著正相关（均P<0.05）。
NSCLC组织中RSK4蛋白阳性表达与癌症晚期、低分化及淋巴结转移显著相关，提示RSK4在NSCLC中可能具有潜在的抑癌作用。这种关联强调了其在NSCLC患者中的预后相关性。
